facebook twitter linkedin
news and events

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE

Selvita Bridges Krakow and San Francisco


San Bruno, CA – March 11, 2016 - Selvita, the largest drug discovery company in Central and Eastern Europe, has just opened its West Coast US office, located in San Bruno, CA.

Selvita has initiated its US operations in September 2015, opening a fully-owned US subsidiary, Selvita Inc., headquartered in Cambridge, MA. Now the company is officially opening its second office, which is dedicated to the support of the ongoing and future projects for business partners from the West Coast of US. The office is located at 1001 Bayhill Drive, in San Bruno, California.
 
The US drug discovery market is absolutely strategic for Selvita. It is not only where most of our revenue comes from, but also where we put most of our hopes in – said Pawel Przewiezlikowski, Chief Executive Officer at Selvita.

We are continuously investing in top class-facilities and best professionals. In 2016 we are opening our second research facility in Poznan, Poland, and we believe we have even more to offer to our customers.

The last several months of our operations on the US East Coast, have shown that our local presence is not only bringing us closer to our US clients, but also facilitating a more swift bidirectional transfer of know-how between our labs in Poland and the partner base in the US. 

Having two US offices located in where the heart of the biotechnology industry beats - in Greater Boston and in the San Francisco Bay areas, is what will definitely bring us closer to achieving our goal of becoming the drug discovery partner of choice for the US biotech and pharma industry.”
 
20160310 182107IMG 2655 2
 
Yesterday, Thursday, March 10, a reception celebrating the opening of Selvita’s West Coast office took place at the EPIC Steak restaurant in San Francisco, CA. The event was held at the Bay Room, offering breathtaking views of the San Francisco Bay and its magnificent Bay Bridge.
 
About Selvita
Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology, as well as provision of integrated drug discovery services. Selvita was established and 2007 and currently employs 327 people, including 102 PhDs, with extensive experience in the area of life sciences. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2016. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita offices are located in Greater Boston Area, San Francisco Area, Cambridge, UK, as well as in Krakow and Poznan, Poland. The company is listed on the Warsaw Stock Exchange (WSE:SLV).